BriaCell Partners With Waisman Biomanufacturing to Manufacture & Supply Prostate Cancer Immunotherapy
BriaCell Therapeutics Corp. has recently entered a manufacturing service agreement with Waisman Biomanufacturing at the University of Wisconsin–Madison (Waisman), to manufacture Bria-Pros, BriaCell’s off-the-shelf personalized immunotherapy for prostate cancer, for anticipated use in clinical studies. Waisman is a leading contract manufacturing organization (CMO) with experience in the manufacturing of cellular therapies for clinical trials.
Under the terms of the agreement, Waisman will be responsible for good manufacturing practice (GMP) manufacturing of Bria-Pros for anticipated use in clinical studies. Waisman’s expert team will be working closely with BriaCell’s scientific and product development teams to ensure timely production of Bria-Pros in compliance with applicable regulatory requirements by the FDA.
Bria-Pros is a novel off-the-shelf personalized immunotherapy for prostate cancer. It includes multiple Human leukocyte antigen (HLA)-specific immunotherapy cell lines that will be administered to patients based on each patient’s HLA type. BriaCell has been developing Bria-Pros as a potentially safe and effective personalized immunotherapy treatment for advanced prostate cancer. BriaCell’s Phase 1/2 trial in prostate cancer is expected to follow upon the completion of the manufacturing, testing, and the related regulatory filings.
“We are very excited to partner with the scientists and experts at Waisman, a leading CMO with extensive experience in the manufacturing of clinical grade cellular therapies, to ensure the rapid production of high-quality immunotherapy supplies for our upcoming clinical trial in prostate cancer. Additionally, this agreement will provide a starting point for our future service agreements as we expand our personalized immunotherapy pipeline into other cancer fields,” stated Dr. Williams, BriaCell’s President & CEO. “We believe that our novel off-the-shelf personalized immunotherapy may offer a safe and effective targeted personalized treatment option for advanced prostate cancer patients who failed the current standard of care.”
According to 2022 Cancer Facts & Figures, prostate cancer, aside from lung cancer, is the most common cancer among men. With an estimated 268,490 new cases diagnosed, 34,500 of men are expected to die of prostate cancer in 2022 making it the second leading cause of cancer death among men. Current treatments for metastatic prostate cancer include immunotherapy, hormone therapy, chemotherapy and targeted treatments. However, none of these treatments are curative. Novel approaches are needed for advanced prostate cancer.
With its state-of-art production facility in Madison, WI, and its expert personnel, Waisman Biomanufacturing has become a leading GMP contract manufacturing organization (CMO) that manufactures a wide range of biotherapeutics for clinical trials. The products include gene therapies, cell therapeutics, and both therapeutic and prophylactic vaccines. For more information, visit https://gmpbio.org.
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. For more information, visit https://briacell.com/.
Total Page Views: 850
